NZ593536A - Quinoline derivatives and methods of use - Google Patents
Quinoline derivatives and methods of useInfo
- Publication number
- NZ593536A NZ593536A NZ593536A NZ59353609A NZ593536A NZ 593536 A NZ593536 A NZ 593536A NZ 593536 A NZ593536 A NZ 593536A NZ 59353609 A NZ59353609 A NZ 59353609A NZ 593536 A NZ593536 A NZ 593536A
- Authority
- NZ
- New Zealand
- Prior art keywords
- benzo
- ylcarbamoyl
- thiazol
- tetrahydroquinolin
- thiazole
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- MPBQJXNTYAFDCG-UHFFFAOYSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=N1 MPBQJXNTYAFDCG-UHFFFAOYSA-N 0.000 abstract 1
- HYGLNHGTGNBVKW-QHHAFSJGSA-N 2-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-5-[(e)-prop-1-enyl]-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=C(/C=C/C)SC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=N1 HYGLNHGTGNBVKW-QHHAFSJGSA-N 0.000 abstract 1
- CCIXRCPQCKVEBP-UHFFFAOYSA-N 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[4-(1,3-benzothiazol-2-ylcarbamoyl)-2,3-dihydro-1,4-benzoxazin-6-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCOC3=CC=2)S1 CCIXRCPQCKVEBP-UHFFFAOYSA-N 0.000 abstract 1
- SWIUTEYEJYYUNU-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-(1-benzylpyrazol-4-yl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=CC=C1C(=C1)C=NN1CC1=CC=CC=C1 SWIUTEYEJYYUNU-UHFFFAOYSA-N 0.000 abstract 1
- GUARKFCLDYLQOJ-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-[3-[4-(dimethylamino)phenoxy]propoxy]pyridine-2-carboxylic acid Chemical compound C1=CC(N(C)C)=CC=C1OCCCOC1=CC=C(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)N=C1C(O)=O GUARKFCLDYLQOJ-UHFFFAOYSA-N 0.000 abstract 1
- WYPAZEMYKBFKQE-UHFFFAOYSA-N 6-[1-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2h-quinolin-7-yl]-3-hydroxypyridine-2-carboxylic acid Chemical compound C1=C(O)C(C(=O)O)=NC(C=2C=C3N(C(=O)NC=4SC5=CC=CC=C5N=4)CCCC3=CC=2)=C1 WYPAZEMYKBFKQE-UHFFFAOYSA-N 0.000 abstract 1
- HRNHYKJWRGNWJS-UHFFFAOYSA-N 6-[4-(1,3-benzothiazol-2-ylcarbamoyl)-1-methyl-2,3-dihydroquinoxalin-6-yl]pyridine-2-carboxylic acid Chemical compound C=1C=C2N(C)CCN(C(=O)NC=3SC4=CC=CC=C4N=3)C2=CC=1C1=CC=CC(C(O)=O)=N1 HRNHYKJWRGNWJS-UHFFFAOYSA-N 0.000 abstract 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000017733 acquired polycythemia vera Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 238000013176 antiplatelet therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000037244 polycythemia vera Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13947908P | 2008-12-19 | 2008-12-19 | |
| PCT/US2009/068400 WO2010080478A1 (en) | 2008-12-19 | 2009-12-17 | Compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ593536A true NZ593536A (en) | 2013-07-26 |
Family
ID=42316717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ593536A NZ593536A (en) | 2008-12-19 | 2009-12-17 | Quinoline derivatives and methods of use |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8114893B2 (enExample) |
| EP (1) | EP2376085B1 (enExample) |
| JP (1) | JP5683484B2 (enExample) |
| KR (1) | KR101633532B1 (enExample) |
| CN (1) | CN102325531B (enExample) |
| AU (1) | AU2009335818A1 (enExample) |
| BR (1) | BRPI0918337A2 (enExample) |
| CA (1) | CA2747161C (enExample) |
| CO (1) | CO6390110A2 (enExample) |
| CR (1) | CR20110389A (enExample) |
| DO (1) | DOP2011000198A (enExample) |
| EC (1) | ECSP11011214A (enExample) |
| ES (1) | ES2462715T3 (enExample) |
| IL (1) | IL213547A0 (enExample) |
| MX (1) | MX2011006514A (enExample) |
| NZ (1) | NZ593536A (enExample) |
| PE (1) | PE20120305A1 (enExample) |
| RU (1) | RU2561109C2 (enExample) |
| SG (1) | SG172266A1 (enExample) |
| WO (1) | WO2010080478A1 (enExample) |
| ZA (1) | ZA201104463B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2134685T3 (en) | 2007-04-16 | 2015-12-07 | Abbvie Inc | 7-unsubstituted indole derivatives as MCL-1 inhibitors |
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| JP5770102B2 (ja) * | 2008-12-19 | 2015-08-26 | ジェネンテック， インコーポレイテッド | 複素環化合物と使用方法 |
| CN102325531B (zh) * | 2008-12-19 | 2014-04-02 | 健泰科生物技术公司 | 化合物和使用方法 |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP2675275B1 (en) | 2011-02-14 | 2017-12-20 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of obesity and related disorders |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| CN103958508B (zh) | 2011-10-14 | 2019-02-12 | 艾伯维公司 | 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂 |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CA2859385A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| ES2727898T3 (es) | 2013-05-02 | 2019-10-21 | Univ Michigan Regents | Amlexanox deuterado con estabilidad metabólica mejorada |
| RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| AU2014338549B2 (en) | 2013-10-25 | 2017-05-25 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| EP3097078B1 (en) * | 2014-01-24 | 2022-05-25 | Purdue Pharma LP | Pyridines and pyrimidines and use thereof |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| WO2015153959A2 (en) | 2014-04-04 | 2015-10-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| CA2954268C (en) * | 2014-07-08 | 2022-11-22 | Dow Agrosciences Llc | Process for the preparation of 3-hydroxypicolinic acids |
| US10071087B2 (en) | 2014-07-22 | 2018-09-11 | Bioventures, Llc | Compositions and methods for selectively depleting senescent cells |
| CN106573947B (zh) * | 2014-07-28 | 2019-11-01 | 默克专利有限公司 | 金属络合物 |
| EP3200786B1 (en) | 2014-10-03 | 2019-08-28 | Novartis AG | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
| EP3230283A1 (en) * | 2014-12-09 | 2017-10-18 | AbbVie Inc. | Bcl-xl inhibitory compounds and antibody drug conjugates including the same |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| US10214536B2 (en) | 2016-01-29 | 2019-02-26 | The Regents Of The University Of Michigan | Amlexanox analogs |
| KR102494039B1 (ko) | 2016-03-28 | 2023-01-30 | 프레시지 바이오싸이언시스, 인크. | 암 치료를 위한 제약학적 조합물 |
| US10807977B2 (en) | 2016-04-21 | 2020-10-20 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| CN108251377B (zh) * | 2018-01-16 | 2021-08-27 | 内蒙古大学 | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| EP3705109A1 (en) | 2019-03-05 | 2020-09-09 | Greenaltech, S.L. | Carotenoids in the treatment of senescence-related diseases |
| US20230322717A1 (en) * | 2020-04-20 | 2023-10-12 | Shenzhen Targetrx, Inc. | Solid form of pyrazine substituted nicotinamide, and preparation and use thereof |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| WO2022008464A1 (en) | 2020-07-06 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| EP4251209A1 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| IL304891A (en) | 2021-02-02 | 2023-10-01 | Servier Lab | Selective Protech BCL-XL compounds and methods of use |
| TW202345857A (zh) * | 2022-03-08 | 2023-12-01 | 美商昂科斯克塞爾醫療有限責任公司 | 他波司他之穩定調配物 |
| IL317103A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of MET inhibitor BCL-XL and methods of using them |
| EP4525925A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| KR20250027285A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법 |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2332756A1 (fr) * | 1975-11-26 | 1977-06-24 | Squibb & Sons Inc | Nouvelles 1, 4-benzoxazin-3(4h)-ones |
| DE19929785A1 (de) | 1999-06-29 | 2001-01-04 | Bayer Ag | Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung |
| US7091227B2 (en) * | 2000-02-07 | 2006-08-15 | Abbott Gmbh & Co. Kg | Benzothiazole derivatives |
| EP1424336A4 (en) | 2001-09-03 | 2004-11-10 | Takeda Chemical Industries Ltd | 1,3-BENZOTHIAZINE DERIVATIVES AND THEIR USE |
| JP4403305B2 (ja) * | 2001-09-03 | 2010-01-27 | 武田薬品工業株式会社 | １，３−ベンゾチアジノン誘導体および用途 |
| SI1463563T1 (sl) | 2001-12-14 | 2009-06-30 | Alcon Inc | Superoksidni dizmutazni mimetiki za zdravljenje očesnih motenj in bolezni |
| CN101253152A (zh) * | 2005-09-02 | 2008-08-27 | 安斯泰来制药株式会社 | 作为rock抑制剂的酰胺衍生物 |
| ES2657635T3 (es) * | 2006-08-08 | 2018-03-06 | Chugai Seiyaku Kabushiki Kaisha | Derivado de pirimidina como inhibidor de PI3K y uso del mismo |
| US8445679B2 (en) | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
| DK2134685T3 (en) | 2007-04-16 | 2015-12-07 | Abbvie Inc | 7-unsubstituted indole derivatives as MCL-1 inhibitors |
| CN101842362A (zh) * | 2007-09-27 | 2010-09-22 | 沃尔特及伊莱萨霍尔医学研究院 | 苯并噻唑化合物 |
| WO2010027002A1 (ja) * | 2008-09-05 | 2010-03-11 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体 |
| JP5770102B2 (ja) | 2008-12-19 | 2015-08-26 | ジェネンテック， インコーポレイテッド | 複素環化合物と使用方法 |
| CN102325531B (zh) | 2008-12-19 | 2014-04-02 | 健泰科生物技术公司 | 化合物和使用方法 |
-
2009
- 2009-12-17 CN CN200980157162.3A patent/CN102325531B/zh active Active
- 2009-12-17 AU AU2009335818A patent/AU2009335818A1/en not_active Abandoned
- 2009-12-17 EP EP09837907.6A patent/EP2376085B1/en active Active
- 2009-12-17 MX MX2011006514A patent/MX2011006514A/es active IP Right Grant
- 2009-12-17 WO PCT/US2009/068400 patent/WO2010080478A1/en not_active Ceased
- 2009-12-17 PE PE2011001249A patent/PE20120305A1/es not_active Application Discontinuation
- 2009-12-17 CA CA2747161A patent/CA2747161C/en active Active
- 2009-12-17 RU RU2011129789/04A patent/RU2561109C2/ru active
- 2009-12-17 ES ES09837907.6T patent/ES2462715T3/es active Active
- 2009-12-17 NZ NZ593536A patent/NZ593536A/xx not_active IP Right Cessation
- 2009-12-17 KR KR1020117016719A patent/KR101633532B1/ko not_active Expired - Fee Related
- 2009-12-17 JP JP2011542420A patent/JP5683484B2/ja active Active
- 2009-12-17 US US12/641,063 patent/US8114893B2/en active Active
- 2009-12-17 SG SG2011044922A patent/SG172266A1/en unknown
- 2009-12-17 BR BRPI0918337A patent/BRPI0918337A2/pt not_active IP Right Cessation
- 2009-12-17 CR CR20110389A patent/CR20110389A/es unknown
-
2011
- 2011-06-14 IL IL213547A patent/IL213547A0/en unknown
- 2011-06-15 ZA ZA2011/04463A patent/ZA201104463B/en unknown
- 2011-06-17 DO DO2011000198A patent/DOP2011000198A/es unknown
- 2011-07-01 CO CO11082793A patent/CO6390110A2/es active IP Right Grant
- 2011-07-18 EC EC2011011214A patent/ECSP11011214A/es unknown
-
2012
- 2012-01-10 US US13/347,364 patent/US8518970B2/en active Active
-
2013
- 2013-06-27 US US13/929,701 patent/US9067928B2/en active Active - Reinstated
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010080478A1 (en) | 2010-07-15 |
| HK1161094A1 (en) | 2012-08-24 |
| RU2561109C2 (ru) | 2015-08-20 |
| ES2462715T3 (es) | 2014-05-26 |
| US8114893B2 (en) | 2012-02-14 |
| MX2011006514A (es) | 2011-10-11 |
| EP2376085A4 (en) | 2012-08-15 |
| AU2009335818A1 (en) | 2011-07-21 |
| KR101633532B1 (ko) | 2016-06-24 |
| PE20120305A1 (es) | 2012-04-09 |
| EP2376085A1 (en) | 2011-10-19 |
| EP2376085B1 (en) | 2014-02-26 |
| BRPI0918337A2 (pt) | 2017-05-30 |
| DOP2011000198A (es) | 2012-08-31 |
| CO6390110A2 (es) | 2012-02-29 |
| US8518970B2 (en) | 2013-08-27 |
| IL213547A0 (en) | 2011-07-31 |
| CA2747161C (en) | 2017-07-18 |
| JP2012512887A (ja) | 2012-06-07 |
| US20140005190A1 (en) | 2014-01-02 |
| US20120184541A1 (en) | 2012-07-19 |
| SG172266A1 (en) | 2011-07-28 |
| CN102325531B (zh) | 2014-04-02 |
| JP5683484B2 (ja) | 2015-03-11 |
| RU2011129789A (ru) | 2013-01-27 |
| ECSP11011214A (es) | 2011-09-30 |
| CA2747161A1 (en) | 2010-07-15 |
| ZA201104463B (en) | 2012-09-26 |
| US20100190782A1 (en) | 2010-07-29 |
| KR20110114581A (ko) | 2011-10-19 |
| CN102325531A (zh) | 2012-01-18 |
| US9067928B2 (en) | 2015-06-30 |
| CR20110389A (es) | 2011-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ593536A (en) | Quinoline derivatives and methods of use | |
| NZ593537A (en) | Isoquinoline derivatives and methods of use | |
| NZ594332A (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| NZ600801A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| MXPA05010086A (es) | Compuestos heterociclicos y metodos de uso. | |
| NZ592508A (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek | |
| TNSN08227A1 (en) | [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases. | |
| PE20120321A1 (es) | Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa | |
| JP2013515032A5 (enExample) | ||
| NZ597647A (en) | Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors | |
| NZ591449A (en) | Picolinamide derivatives as kinase inhibitors | |
| PE20090717A1 (es) | Derivados de quinolina como inhibidores de la pi3 quinasa | |
| PE20090887A1 (es) | DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6 | |
| PE20091268A1 (es) | Derivados heterociclicos como inhibidores de pi3 quinasa | |
| ATE423112T1 (de) | Dipyridyl-dihydropyrazolone und ihre verwendung 4-(pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivate als spezifische hemmstoffe der hif-prolyl-4-hydroxylasen zur behandlung kardiovaskulärer und hämatologischer erkrankungen | |
| NZ622769A (en) | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection | |
| EA200901608A1 (ru) | Производные хинаксолина в качестве ингибиторов тирозинкиназной активности киназ janus | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| NZ602726A (en) | Pyrazolyl quinoxaline kinase inhibitors | |
| MX2012002179A (es) | Compuestos heterociclicos de oxima. | |
| NO20070453L (no) | Kondenserte heterocykliske kinase inhibitorer | |
| HRP20160096T1 (hr) | Supstituirani derivati izokinolina | |
| PE20090041A1 (es) | Derivados de triazol como inhibidores de la biosintesis de leucotrienos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 DEC 2016 BY AJ PARK Effective date: 20131120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 DEC 2019 BY THOMSON REUTERS Effective date: 20140320 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2020 BY THOMSON REUTERS Effective date: 20191116 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2021 BY THOMSON REUTERS Effective date: 20200926 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2022 BY THOMSON REUTERS Effective date: 20211102 |
|
| LAPS | Patent lapsed |